CCO extends its June run to close at CAD 154.68, but the peer group has stalled — making this week's modest gain read differently from last week's sector-wide surge.
Four days ago the uranium complex was moving together. That synchrony has broken down. NXE slipped 1.1% on the week, DML gave back 0.6%, ISO fell 5.4%, and UEC dropped 2.8%. Cameco bucked the drift, adding 2.4% to build on last week's 7% advance. The stock is now up nearly 7% on the month. The previous note flagged Cameco moving with the tide rather than leading it — this week, that relationship inverted, at least modestly.
The short base has grown, though it remains too small to drive a meaningful narrative on its own. Short interest climbed roughly 20% on the week to reach 0.72% of free float — up from 0.58% flagged in the June 20 note — and has risen 45% over the past month. The one-week jump from around 2.5 million shares to 3.1 million is the sharpest single-week move in the 30-day window. Despite that acceleration, the lending market is entirely relaxed. Availability runs at over 5,000% — meaning shares available to borrow dwarf the current short position by a factor of roughly 50 — and borrowing costs are negligible at 0.51%. This is not a short setup under pressure; it looks more like fresh positioning being laid on into a momentum run.
The valuation picture keeps a lid on enthusiasm. Cameco trades at a trailing P/E near 73x and an EV/EBITDA around 31x, both of which have compressed slightly over the past 30 days as the stock has rallied and earnings estimates have firmed. The short score ranks in the 85th percentile of the ORTEX universe — meaning the stock screens as having less short-side interest than most names — while EPS momentum over 30 days scores at the 68th percentile. The forward earnings growth score tells the other side: at the 23rd percentile, the market is paying premium multiples for a business where near-term EPS acceleration is not yet baked into consensus. The most recent note on NAV per share flagged an improvement to $66 from $58, pointing to stronger underlying uranium fundamentals, but at current multiples that is already reflected in the price.
Institutional ownership is broadly stable. Mirae Asset leads at 3.5% of shares outstanding, followed by Capital Research at 3.2% and Vanguard at 2.7%. Several managers added modestly in the most recent reporting window — Van Eck lifted its position by 651,000 shares, BMO by 772,000 — consistent with ongoing passive and thematic nuclear-energy accumulation rather than any aggressive tactical shift. Insider activity is low-significance: the most recent disclosed trades were small VP-level sells in March and April, none of which carry material signal.
Q2 earnings land on July 31. The last print produced a 5.2% single-day drop followed by an 8.6% five-day decline — the clearest earnings-reaction data in the history window — so the next test is whether the stock's re-rating since then can hold through a results day that has historically been an exit catalyst rather than a continuation signal. Whether shorts accumulating into that date are pre-positioning for a similar outcome, or simply hedging long uranium exposure, is the question worth tracking over the next five weeks.
See the live data behind this article on ORTEX.
Open CCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
